Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2003
10/16/2003US20030195202 Inhibitors of IMPDH enzyme
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195197 Non-nucleoside reverse transcriptase inhibitors
10/16/2003US20030195196 Pyrrolobenzodiazepines
10/16/2003US20030195179 Redispersibility comprising polyvinylpyrrolidone and a water-soluble anionic macromolecular compound which are added to prevent a hardly soluble drug from adhering to a container and forming aggregates
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195159 HIV protease inhibitors based on amino acid derivatives
10/16/2003US20030195150 Antimicrobial peptides
10/16/2003US20030195144 Antimicrobial compounds and formulations
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194747 Convergent combinatory peptide libraries and their use for vaccination against hepatitis c virus
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194725 Creating a database of related protein/nucleic acid sequences with annotations of the potential disease associations of the sequences; testing the potential disease associations by means of a biological assay and validating the disease association
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194694 Pure recombinant influenza virus comprising a mutant ion channel protein which lacks or has reduced activity relative to the wild-type
10/16/2003US20030194447 Antiseptic compositions and methods
10/16/2003US20030194441 Antibacterial aqueous solutioncomprises: methylcellulose; citric acid; polyethylene glycol and an active drug component, especially a quinolone antibiotic; viscosity of 12 mPa.s or below at 20 degrees C.
10/16/2003US20030194439 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/16/2003US20030194414 Replikin peptides and antibodies therefore
10/16/2003US20030194411 Peptide compositions for the treatment and prevention of HIV infection
10/16/2003US20030194408 Antibody which specifically binds to at least two variants of an epitope of an HIV-1 Tat protein
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481976A1 Novel thyroid receptor ligands
10/16/2003CA2481925A1 Therapeutic agent for patients having human fc.gamma.riiia
10/16/2003CA2481920A1 Antibody composition-containing medicament
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481837A1 Production process for antibody composition
10/16/2003CA2481658A1 Method of enhancing of binding activity of antibody composition to fcy receptor iiia
10/16/2003CA2481657A1 Cells of which genome is modified
10/16/2003CA2481656A1 Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2480824A1 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480692A1 Chemokines mutants having improved oral bioavailability
10/16/2003CA2480482A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
10/16/2003CA2480196A1 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2479777A1 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
10/16/2003CA2478930A1 Epitope constructs comprising antigen presenting cell targeting mechanisms
10/16/2003CA2476545A1 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
10/15/2003EP1352960A1 Antiviral therapy on the basis of RNA interference
10/15/2003EP1352955A2 HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
10/15/2003EP1352907A1 Processes for preparing calanolide a and intermediates thereof
10/15/2003EP1352660A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
10/15/2003EP1352657A1 Interferon therapeutic effect-potentiating agents
10/15/2003EP1352655A1 Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
10/15/2003EP1352062A2 Improved growth hormone molecules
10/15/2003EP1352061A2 Method for inhibiting the expression of a target gene
10/15/2003EP1352053A2 Method for processing dendritic cells and for activating macrophages with ru 41740
10/15/2003EP1352052A1 Ancillary composition for the preparation of committed mature dentritic cells
10/15/2003EP1351978A2 Retrovirus isolated from humans
10/15/2003EP1351977A1 Antimicrobial pseudopeptides
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351960A1 Improved preparation of (4r, 5s, 6s)-3-[[(2r,3r)-2-[[[(s)-2-amino-3-methyl-1-oxobutyl]methyl]tetrahydro-3-furanyl]thio]-6-[(r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
10/15/2003EP1351959A1 Novel pleuromutilin derivatives
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351953A1 Quinoline derivatives as nk-3 antagonists
10/15/2003EP1351940A1 Substituted quinolines for the treatment of protozoan and retrovirus co-infections
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351933A1 Il-8 receptor antagonists
10/15/2003EP1351929A1 Nitric oxide synthase inhibitor phosphate salt
10/15/2003EP1351924A2 Diamines as modulators of chemokine receptor activity
10/15/2003EP1351916A2 Ether compounds and compositions for cholesterol management and related uses
10/15/2003EP1351708A1 Therapeutic agent comprising a b-subunit of a protein toxin
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351702A1 Trem-1 splice variant for use in modifying immune responses
10/15/2003EP1351701A2 Active metabolite of antifungal compound
10/15/2003EP1351699A1 Methods for improved diagnosis and treatment of mycobacterial infections
10/15/2003EP1351681A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
10/15/2003EP1351680A2 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
10/15/2003EP1351678A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
10/15/2003EP1351677A2 Method for treating cancer
10/15/2003EP1351672A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
10/15/2003EP1268471B1 N-heterocyclic derivatives as nos inhibitors
10/15/2003EP1265873B1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents
10/15/2003EP1183037B1 Compositions for modulating immune response and for the treatment of inflammatory disease
10/15/2003EP1071409B1 Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
10/15/2003EP0954296B1 Use of bronopol for the treatment of diseases in fish
10/15/2003EP0916651B1 Phenylalkylcarboxylic acid derivatives
10/15/2003EP0796276B1 Gradual modification, super-agonists and antagonists of signal-proteins and peptides
10/15/2003EP0766674B1 New hiv protease inhibitors
10/15/2003EP0585398B1 Hcv genomic sequences for diagnostics and therapeutics
10/15/2003CN1449446A Streptococcus antigens
10/15/2003CN1449443A 真菌细胞壁合成基因 Fungal cell wall synthesis genes
10/15/2003CN1449440A Masp-2, a complement-fixing enzyme, and uses for it
10/15/2003CN1449407A Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acidor a glutamine in the form of physiologically acceptable
10/15/2003CN1449399A Polycyclic xanthones as antibiotics
10/15/2003CN1449384A Novel ester or amide derivatives
10/15/2003CN1449293A Multivalent vaccine composition
10/15/2003CN1449290A Combinations of dalfopristine/quinupristine with cefpirome
10/15/2003CN1449287A Fused pyrrolocarbazoles against inflammation
10/15/2003CN1449285A Use of il-8 receptor antagonists in the treatment of virus infections
10/15/2003CN1449273A Antimicotic nail varnish composition
10/15/2003CN1449271A Method and manufacture of a wound dressing for covering an open wound
10/15/2003CN1448400A Synthetic method of 24-methylene-cholesterol-3 beta, 5 alpha, 6 beta,19-tetraalcohol
1 ... 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 ... 1798